AR117102A1 - Inhibidores de arg1 y/o arg2 - Google Patents
Inhibidores de arg1 y/o arg2Info
- Publication number
- AR117102A1 AR117102A1 ARP190103373A ARP190103373A AR117102A1 AR 117102 A1 AR117102 A1 AR 117102A1 AR P190103373 A ARP190103373 A AR P190103373A AR P190103373 A ARP190103373 A AR P190103373A AR 117102 A1 AR117102 A1 AR 117102A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- considered individually
- cycloalkyl
- substitutions
- Prior art date
Links
- 102100021723 Arginase-1 Human genes 0.000 title abstract 3
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 title abstract 3
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 title abstract 3
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 title abstract 3
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000006467 substitution reaction Methods 0.000 abstract 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 2
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- -1 C1−8 alkylC (O) - Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se dan a conocer compuestos que son inhibidores de al menos uno de ARG1 y ARG2, y composiciones que contienen los compuestos, así como métodos para sintetizar los compuestos. También se da a conocer en la presente memoria el uso de dichos compuestos para el tratamiento de una amplia variedad de enfermedades, trastornos, y afecciones, incluidos los trastornos relacionados con el cáncer y el sistema inmunitario que son mediados, al menos en parte, por ARG1 y ARG2. Reivindicación 1: Un compuesto que posee la fórmula (1) o una sal, hidrato o solvato del mismo apto para uso farmacéutico, donde, X es N o CR⁴ᵃ; cada R¹ considerado en forma individual e independiente es H o C₁₋₈ alquilo; R² es H o CH₃; cada R³ considerado en forma individual e independiente es H o C₁₋₈ alquilo; o dos grupos R³ están unidos para formar conjuntamente un anillo de 5 ó 6 miembros que no posee sustituciones o está sustituido con de 1 a 4 Rᵃ; cada R⁴ᵃ, R⁴ᵇ, R⁴ᶜ y R⁴ᵈ considerado en forma individual e independiente se selecciona a partir del grupo que consiste en H, halógeno, CN, C₁₋₈ alquilo, C₁₋₈ alcoxi, C₁₋₈ hidroxialquilo, C₁₋₈ haloalquilo, C₁₋₈ haloalcoxi, -X¹-Y, -X¹-SO₂R⁵ᵃ y -X¹-NR⁵ᵇR⁵ᶜ; cada R⁵ᵃ, R⁵ᵇ y R⁵ᶜ considerado en forma individual e independiente se selecciona a partir del grupo que consiste en H, C₁₋₈ alquilo, C₁₋₈ haloalquilo, C₁₋₈ alquilC(O)-, C₃₋₇ cicloalquilo, heterocicloalquilo de 3 a 7 miembros, arilo, heteroarilo y un aminoácido, o R⁵ᵇ y R⁵ᶜ están unidos para formar conjuntamente un anillo de 4 a 6 miembros; y donde cada uno de anillo de 4 a 6 miembros, C₃₋₇ cicloalquilo o heterocicloalquilo de 3 a 7 miembros, arilo y heteroarilo, no poseen sustituciones o están sustituidos con de 1 a 4 Rᵇ; cada X¹ es un enlace, -O-, C₁₋₆ alquileno o -O-C₁₋₆ alquileno, donde las porciones de alquileno no poseen sustituciones o están sustituidos con 1 a 4 Rᶜ y 0 ó 1 oxo; cada Rᵃ, Rᵇ y Rᶜ considerado en forma individual e independiente es halógeno, CN, OH, NH₂, CO₂H, C₁₋₄ alquilo, C₁₋₄ haloalquilo, C₃₋₆ cicloalquilo y fenilo, o dos Rᶜ se combinan para formar un C₃₋₆ cicloalquilo que no posee sustituciones o está sustituido con 1 a 3 Rᵈ; cada Y considerado en forma individual e independiente es fenilo, un heteroarilo de 5 ó 6 miembros, heterocicloalquilo de 3 a 7 miembros, o C₃₋₆ cicloalquilo, cada uno de los cuales no posee sustituciones o está sustituido con de 1 a 3 Rᵈ; y cada Rᵈ considerado en forma individual e independiente es halógeno, C₁₋₄ alquilo, amino, aminoC₁₋₄ alquilo, C₁₋₄ haloalquilo, OH, y C₁₋₄ hidroxialquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862768284P | 2018-11-16 | 2018-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117102A1 true AR117102A1 (es) | 2021-07-14 |
Family
ID=70731928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103373A AR117102A1 (es) | 2018-11-16 | 2019-11-15 | Inhibidores de arg1 y/o arg2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12226425B2 (es) |
| EP (1) | EP3880685B1 (es) |
| JP (1) | JP7461350B2 (es) |
| KR (1) | KR102718333B1 (es) |
| CN (1) | CN113382998A (es) |
| AR (1) | AR117102A1 (es) |
| AU (1) | AU2019379808C1 (es) |
| CA (1) | CA3120196A1 (es) |
| ES (1) | ES3034676T3 (es) |
| TW (1) | TWI828800B (es) |
| UY (1) | UY38476A (es) |
| WO (1) | WO2020102646A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7474861B2 (ja) | 2020-03-19 | 2024-04-25 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物 |
| JP7776448B2 (ja) | 2020-06-02 | 2025-11-26 | アーカス バイオサイエンシズ インコーポレイティド | Ｔｉｇｉｔに対する抗体 |
| US11649261B2 (en) | 2020-06-17 | 2023-05-16 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
| JP2024521712A (ja) | 2021-05-21 | 2024-06-04 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ａｘｌ阻害化合物 |
| IL312348A (en) | 2021-10-29 | 2024-06-01 | Arcus Biosciences Inc | HIF-2ALPHA inhibitors and methods of using it |
| KR20250006959A (ko) | 2022-05-02 | 2025-01-13 | 아르커스 바이오사이언시즈 인코포레이티드 | 항-tigit 항체 및 이의 용도 |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| US20260028336A1 (en) | 2022-07-20 | 2026-01-29 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| AU2023341373A1 (en) | 2022-09-14 | 2025-03-06 | Arcus Biosciences, Inc. | Dispersions of etrumadenant |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| KR20250080902A (ko) | 2022-10-20 | 2025-06-05 | 아르커스 바이오사이언시즈 인코포레이티드 | Cd73 화합물의 동결건조된 제형 |
| US20240425497A1 (en) | 2023-05-05 | 2024-12-26 | Arcus Biosciences, Inc. | Cbl-b Inhibitors and Methods of Use Thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202517260A (zh) | 2023-10-06 | 2025-05-01 | 美商阿克思生物科學有限公司 | Ｃｂｌ—ｂ抑制劑及其使用方法 |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| EP1049660A1 (en) | 1997-10-10 | 2000-11-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| US7163923B2 (en) | 2001-05-09 | 2007-01-16 | Celmed Oncology (Usa), Inc. | Peptide deformylase activated prodrugs |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN101983066B (zh) | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | 基于酯的胰岛素前药 |
| KR101691093B1 (ko) | 2008-06-17 | 2016-12-29 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 보로네이트 에스테르 화합물 및 이의 제약학적 조성물 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| SMT202500126T1 (it) | 2008-12-09 | 2025-05-12 | Hoffmann La Roche | Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t |
| EP2376072A1 (en) | 2008-12-29 | 2011-10-19 | Tartu Ülikool (University Of Tartu) | Arginase inhibitors for the treatment of depression |
| JP2012515799A (ja) | 2009-01-26 | 2012-07-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | アルギナーゼ阻害剤および使用方法 |
| CA3067609A1 (en) | 2009-09-03 | 2011-03-10 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
| KR20180049198A (ko) | 2009-09-25 | 2018-05-10 | 샤이어 오펀 테라피즈 게엠베하 | 신규한 ｎｐｒ－ｂ 길항제 |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| LT2542256T (lt) | 2010-03-04 | 2019-10-25 | Macrogenics Inc | Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| BR112012020372A8 (pt) | 2010-03-05 | 2018-01-02 | Hoffmann La Roche | anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante |
| US9040703B2 (en) | 2010-04-22 | 2015-05-26 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| PT2566517T (pt) | 2010-05-04 | 2019-01-24 | Five Prime Therapeutics Inc | Anticorpos que ligam csf1r |
| CA2810359C (en) | 2010-09-09 | 2021-06-22 | Pfizer Inc. | 4-1bb binding molecules |
| JP5909239B2 (ja) | 2010-10-26 | 2016-04-26 | マーズ インコーポレイテッド | アルギナーゼ阻害剤としてのボロネート |
| JP2014506253A (ja) | 2010-12-31 | 2014-03-13 | コリドー ファーマシューティカルズ インコーポレイテッド | アルギナーゼ阻害剤およびその使用法 |
| ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
| BR112014009415B1 (pt) | 2011-10-19 | 2021-11-23 | Mars, Incorporated | Composição farmacêutica, composto inbidor de arginase e seus usos |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| KR20140113683A (ko) | 2011-12-15 | 2014-09-24 | 에프. 호프만-라 로슈 아게 | 인간 csf-1r에 대한 항체 및 이의 용도 |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| MX355758B (es) | 2012-04-18 | 2018-04-27 | Mars Inc | Analogos constreñidos en el anillo como inhibidores de arginasa. |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| WO2014007831A1 (en) | 2012-07-06 | 2014-01-09 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EP3008051A4 (en) | 2013-06-12 | 2017-03-01 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| US9663491B2 (en) | 2014-04-15 | 2017-05-30 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
| CL2014002403A1 (es) | 2014-09-11 | 2015-01-09 | Univ Pontificia Catolica Chile | Metodo para la preparacion enantioselectiva y purificacion del acido 2(s)-amino-6-boronohexanoico (abh) a partir de la disolucion de bpb-ni-gly en tetrahidrofurano, neutralizacion y posterior extraccion con diclorometano, disolucion en un alcohol c1-c5, enfriamiento para lograr la precipitacion de bpb, obtencion de abh y su posterior purificacion. |
| WO2016100555A1 (en) | 2014-12-18 | 2016-06-23 | Inception 4, Inc. | Boronic acid derivatives and uses thereof |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EA201890113A1 (ru) * | 2015-06-23 | 2018-07-31 | Калитера Байосайенсиз, Инк. | Композиции и способы ингибирования активности аргиназы |
| CA3003271A1 (en) | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2018022664A1 (en) | 2016-07-26 | 2018-02-01 | Flagship Pioneering, Inc. | Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases |
| AU2017356942A1 (en) * | 2016-11-08 | 2019-05-23 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| SG11202008113RA (en) | 2018-03-05 | 2020-09-29 | Arcus Biosciences Inc | Arginase inhibitors |
| US11274111B2 (en) | 2018-06-20 | 2022-03-15 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
-
2019
- 2019-11-15 UY UY0001038476A patent/UY38476A/es not_active Application Discontinuation
- 2019-11-15 JP JP2021526441A patent/JP7461350B2/ja active Active
- 2019-11-15 CN CN201980089420.2A patent/CN113382998A/zh active Pending
- 2019-11-15 WO PCT/US2019/061657 patent/WO2020102646A2/en not_active Ceased
- 2019-11-15 AU AU2019379808A patent/AU2019379808C1/en active Active
- 2019-11-15 TW TW108141665A patent/TWI828800B/zh active
- 2019-11-15 AR ARP190103373A patent/AR117102A1/es not_active Application Discontinuation
- 2019-11-15 ES ES19884624T patent/ES3034676T3/es active Active
- 2019-11-15 CA CA3120196A patent/CA3120196A1/en active Pending
- 2019-11-15 EP EP19884624.8A patent/EP3880685B1/en active Active
- 2019-11-15 US US17/294,353 patent/US12226425B2/en active Active
- 2019-11-15 KR KR1020217018476A patent/KR102718333B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI828800B (zh) | 2024-01-11 |
| EP3880685B1 (en) | 2025-06-18 |
| TW202033203A (zh) | 2020-09-16 |
| KR102718333B1 (ko) | 2024-10-17 |
| KR20210108954A (ko) | 2021-09-03 |
| AU2019379808C1 (en) | 2024-01-25 |
| WO2020102646A2 (en) | 2020-05-22 |
| ES3034676T3 (en) | 2025-08-21 |
| CA3120196A1 (en) | 2020-05-22 |
| EP3880685A4 (en) | 2022-07-27 |
| AU2019379808B2 (en) | 2023-08-03 |
| JP2022507474A (ja) | 2022-01-18 |
| EP3880685A2 (en) | 2021-09-22 |
| EP3880685C0 (en) | 2025-06-18 |
| UY38476A (es) | 2020-06-30 |
| WO2020102646A3 (en) | 2020-08-13 |
| JP7461350B2 (ja) | 2024-04-03 |
| US20220016143A1 (en) | 2022-01-20 |
| US12226425B2 (en) | 2025-02-18 |
| AU2019379808A1 (en) | 2021-06-24 |
| CN113382998A (zh) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR120684A1 (es) | INHIBIDORES DE HIF-2a | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR117398A1 (es) | Inhibidores de la señalización mediada por tirosina cinasa 2 | |
| AR114971A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR118826A1 (es) | Inhibidores de cinasas raf | |
| EA201992082A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR079689A1 (es) | Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias. | |
| BR112018015413A2 (pt) | inibidores de indoleamina-2,3-dioxigenase (ido) | |
| AR103561A1 (es) | Fenilpiridinas herbicidas | |
| AR090292A1 (es) | Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| AR093308A1 (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
| AR088810A1 (es) | Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR075249A1 (es) | Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles, metodo de preparacion de los mismos e intermediarios de dicha sintesis, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer, artritis, alergias y otras enfermedades. | |
| AR102427A1 (es) | Derivados de carbazol inhibidores de quinasas | |
| EA201401082A1 (ru) | Фармацевтические препараты, содержащие антагонисты ccr3 | |
| EA201992771A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |